Table 2 Group distribution based on treatment
Variables | Total (n = 161) | Group A (n = 73) | Group B (n = 88) | p |
|---|---|---|---|---|
Oxygen Therapy | ||||
Nasal Mask | 3 (1.9%) | 1 (33.3%) | 2 (66.7%) | 0.022 |
Non-invasive Mechanical Ventilation | 129 (80.1%) | 65 (50.4%) | 64 (49.6%) | |
Invasive Mechanical Ventilation | 29 (18.0%) | 7 (24.1%) | 22 (75.9%) | |
Duration of Non-invasive Mechanical Ventilation (days) | 7 (1–28) | 6 (1–16) | 10 (2–28) | < 0.001 |
Duration of Invasive Mechanical Ventilation (days) | 11 (4–22) | 7 (4–22) | 12 (4–18) | 0.098 |
Corticosteroid Therapy | ||||
Methylprednisolone | 129 (80.1%) | 55 (42.6%) | 74 (57.4%) | 0.166 |
Dexamethasone | 59 (36.6%) | 26 (44.1%) | 33 (55.9%) | 0.805 |
Pulse Steroid | 16 (9.9%) | 9 (56.7%) | 7 (43.8%) | 0.356 |
Steroid Dose | ||||
< 1 mg/kg ED | 83 (51.6%) | 47 (56.6%) | 36 (43.4%) | 0.002 |
> 1 mg/kg ED | 78 (48.4%) | 26 (33.3%) | 52 (66.7%) | |
Duration of Steroid Use (days) | 17 (2–50) | 15 (2–33) | 21 (6–50) | < 0.001 |
Time to Start Insulin After Steroid Use (days) | - | 8 (1–45) | ||
Tocilizumab | 21 (13.0%) | 11 (52.2%) | 10 (47.8%) | 0.487 |
Immune Plasma | 124 (77.0%) | 54 (43.5%) | 70 (56.5%) | 0.403 |
Cytokine Filter | 8 (5.0%) | 1 (12.5%) | 7 (87.5%) | 0.056 |